Ishida Y, Yano K, Ito T, Shigematus H, Sasaki K, Kondo S, Kuriya S
Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan.
Thromb Haemost. 2001 Feb;85(2):349-55.
In this study, the protein which stimulates proplatelet formation (PPF) of megakaryocytes was purified from normal human plasma using 7 steps procedures. Two different protease inhibitors were identified based on their amino acid sequences, i.e. antithrombin III (AT III) and C1 inhibitor. They were included in high density lipoprotein (HDL). HDL was necessary for AT III to be active in PPF in vitro. The biological effects of the AT III/HDL or thrombin-AT III (TAT)/HDL were studied in vitro. PPF of murine megakaryocytes was stimulated by negative control (BSA) (1.8 +/- 0.3%), AT III (2.0 +/- 0.4%), HDL (1.2 +/- 0.9%), AT III/HDL (14.8 +/- 2.1%) or TAT/HDL (23.3 +/- 3.5%), respectively. TAT/HDL also had a synergistic effect with the mpl ligand, judging by the acetylcholinesterase (AchE) expression of murine megakaryocytes (2.7 fold increase). In vivo subcutaneous administration of AT III alone or TAT for 3 days significantly stimulated thrombocytosis (136% and 144%, respectively, p<0.05) and AT III/HDL showed rapid and further stimulation (150%, p <0.01). These results and the previous studies indicate that megakaryocytopoiesis is regulated by the mpl ligand, while a protease/protease inhibitor complex such as TAT, which is involved in the coagulation cascade associated with platelet consumption, might be one of the regulators in platelet production.
在本研究中,采用七步程序从正常人血浆中纯化出刺激巨核细胞前血小板形成(PPF)的蛋白质。基于其氨基酸序列鉴定出两种不同的蛋白酶抑制剂,即抗凝血酶III(AT III)和C1抑制剂。它们存在于高密度脂蛋白(HDL)中。HDL是AT III在体外对PPF发挥活性所必需的。对AT III/HDL或凝血酶 - AT III(TAT)/HDL的生物学效应进行了体外研究。小鼠巨核细胞的PPF分别受到阴性对照(牛血清白蛋白)(1.8±0.3%)、AT III(2.0±0.4%)、HDL(1.2±0.9%)、AT III/HDL(14.8±2.1%)或TAT/HDL(23.3±3.5%)的刺激。从小鼠巨核细胞的乙酰胆碱酯酶(AchE)表达情况判断(增加2.7倍),TAT/HDL与mpl配体也具有协同效应。体内皮下单独给予AT III或TAT 3天可显著刺激血小板增多(分别为136%和144%,p<0.05),而AT III/HDL显示出快速且进一步的刺激作用(150%,p<0.01)。这些结果以及先前的研究表明,巨核细胞生成受mpl配体调节,而参与与血小板消耗相关的凝血级联反应的蛋白酶/蛋白酶抑制剂复合物,如TAT,可能是血小板生成的调节因子之一。